We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: thuốc ức chế PCSK9
MedXY News
EnglishTag

thuốc ức chế PCSK9

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationcritical carebiomarkersartificial intelligencetype 1 diabetesclinical trialsHypertensiononcologyCardiologyMortalitypublic healthcardiovascular diseasediabetesAlzheimer's diseaseepidemiologybreast cancer

Latest news

Tag

PCSK9 Inhibitors and Their Protective Role Against Retinal Vascular Occlusions in Hyperlipidemic Patients
Cardiologyhyperlipidemiaretinal artery occlusion

PCSK9 Inhibitors and Their Protective Role Against Retinal Vascular Occlusions in Hyperlipidemic Patients

By MedXY|Oct 11, 2026

PCSK9 inhibitors significantly reduce the risk of retinal vascular occlusions compared to other lipid-lowering therapies in patients with hyperlipidemia, highlighting their potential as a neuroprotective cardiovascular intervention.

Evaluating PCSK9 Inhibitor Effects on Outcomes in ASCVD Patients Without Prior Ischemic Events: Real-World Insights
CardiologyNghiên cứu quan sátischemic events
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story

Evaluating PCSK9 Inhibitor Effects on Outcomes in ASCVD Patients Without Prior Ischemic Events: Real-World Insights

By MedXY|Aug 17, 2026

This observational study shows PCSK9 inhibitor monoclonal antibodies significantly reduce ischaemic events and mortality over five years in patients with ASCVD but no prior ischemic events, highlighting their preventive potential in routine

Evolution and Future Frontiers of PCSK9 Inhibition: From Genetic Discovery to Genomic Medicine
Clinical Updatescardiovascular outcomesgene therapy

Evolution and Future Frontiers of PCSK9 Inhibition: From Genetic Discovery to Genomic Medicine

By MedXY|Mar 25, 2026

This review synthesizes the trajectory of PCSK9 inhibitors, from pivotal monoclonal antibody trials to emerging RNA interference and gene-editing technologies, emphasizing their role in achieving ultra-low LDL-C levels and reducing major ad

Beyond Statins: The Evolution and Clinical Impact of PCSK9 Inhibition in Cardiovascular Risk Management
Cardiologycardiovascular diseaseLDL Cholesterol

Beyond Statins: The Evolution and Clinical Impact of PCSK9 Inhibition in Cardiovascular Risk Management

By MedXY|Mar 21, 2026

This article explores the transformation of lipid management through PCSK9 inhibitors. From genetic discovery to landmark cardiovascular outcomes trials, we examine how monoclonal antibodies, RNA interference, and gene editing are redefinin

High Lipoprotein(a) Predicts Recurrent ASCVD — Intensified LDL‑Lowering, Especially PCSK9 Inhibitors, May Attenuate Risk
CardiologyLipoprotein(a)thuốc ức chế PCSK9

High Lipoprotein(a) Predicts Recurrent ASCVD — Intensified LDL‑Lowering, Especially PCSK9 Inhibitors, May Attenuate Risk

By MedXY|Dec 2, 2025

In 273,770 US patients with established ASCVD, rising lipoprotein(a) (nmol/L) was steadily associated with higher risk of recurrent events; the excess risk was partially blunted in those receiving high‑impact LDL‑lowering therapy, most nota

PCSK9 Inhibition Prevents First Major Cardiovascular Events: VESALIUS‑CV trial
Cardiologycardiovascular outcomesEvolocumab

PCSK9 Inhibition Prevents First Major Cardiovascular Events: VESALIUS‑CV trial

By MedXY|Nov 9, 2025

In the VESALIUS‑CV trial, evolocumab reduced first major adverse cardiovascular events by 25% (3‑point MACE) and 19% (4‑point MACE) versus placebo over 4.6 years in patients with atherosclerosis or diabetes and no prior MI or stroke.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Cardiology
Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models